Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Study sponsor: Imunon
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2032-10-31Estimated
Enrollment · participants500Estimated
Source updated2026-11-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.